In a patient with a thyroid‑stimulating hormone level of 0.27 mIU/L after starting levothyroxine 137 µg daily, what is the appropriate diagnosis?

Exogenous Subclinical Hyperthyroidism Due to Levothyroxine Overtreatment

The appropriate diagnosis is exogenous subclinical hyperthyroidism (or iatrogenic subclinical hyperthyroidism) caused by excessive levothyroxine replacement. With a TSH of 0.27 mIU/L in a patient taking levothyroxine 137 mcg daily, the patient is receiving more thyroid hormone than needed, resulting in suppression of TSH below the normal reference range (typically 0.45-4.5 mIU/L) while free T4 and T3 remain within normal limits 1.

Diagnostic Classification

This TSH level falls into the mild exogenous subclinical hyperthyroidism category (TSH 0.1-0.45 mIU/L) according to established guidelines 1. The key distinguishing features are:

• TSH suppressed below normal range (0.27 mIU/L is below the typical lower limit of 0.45 mIU/L)
• Patient is on levothyroxine therapy (exogenous cause)
• Presumed normal free T4 and T3 (would need confirmation, but diagnosis implies subclinical rather than overt hyperthyroidism)

Critical Next Steps

You must first confirm this is truly subclinical hyperthyroidism by measuring free T4 and total T3 (or free T3) to ensure they remain within normal limits 1. If free T4 or T3 are elevated, the diagnosis would shift to overt hyperthyroidism requiring more aggressive dose reduction.

Management Algorithm

Step 1: Review the Indication for Levothyroxine

The management depends entirely on why the patient is taking levothyroxine 1:

• If treating simple hypothyroidism (no thyroid cancer, no nodules): Reduce the levothyroxine dose to bring TSH back into the normal reference range
• If treating thyroid cancer or suppressing thyroid nodules: Consult with the treating endocrinologist, as intentional TSH suppression may be the therapeutic goal

Step 2: Dose Adjustment (For Simple Hypothyroidism)

Decrease levothyroxine by 12.5-25 mcg daily 1. Given the current dose of 137 mcg, reducing to 112-125 mcg would be appropriate. The guideline specifically notes that dose adjustment is "particularly important when the serum TSH is in the lower part of the range" 1.

Step 3: Monitoring

• Recheck TSH in 6-8 weeks after dose adjustment 2, 3
• Continue adjusting in 12.5-25 mcg increments until TSH normalizes
• Once stable, monitor every 6-12 months 2

Clinical Risks of Untreated Exogenous Subclinical Hyperthyroidism

While the evidence for harm at this TSH level (0.1-0.45 mIU/L) is limited, there are important considerations 1:

• Cardiovascular risks: Possible increased cardiovascular mortality, particularly in elderly patients (>60 years) 1
• Atrial fibrillation: Increased risk, especially in older patients 1
• Bone loss: Risk of decreased bone mineral density and fractures, particularly in postmenopausal women 1
• Cardiac dysfunction: Increased heart rate, left ventricular mass, and diastolic dysfunction 1

The guidelines recommend against routine treatment for all patients with TSH 0.1-0.45 mIU/L when endogenous, but explicitly recommend dose reduction when exogenous (levothyroxine-induced) 1. This is a critical distinction—your patient's condition is iatrogenic and correctable simply by adjusting medication.

Common Pitfalls to Avoid

1. Don't ignore mildly suppressed TSH in levothyroxine-treated patients: Even though TSH is only mildly low, guidelines are clear that the dose should be reduced for simple hypothyroidism 1

2. Don't assume the patient needs this dose: The dose of 137 mcg may have been appropriate initially but requirements change with age, weight loss, or resolution of transient thyroid dysfunction 2

3. Don't delay dose adjustment in elderly or cardiac patients: These patients are at highest risk for adverse cardiovascular outcomes from even mild TSH suppression 1, 3

4. Rule out non-compliance or malabsorption issues: If TSH doesn't normalize with dose reduction, consider whether the patient was previously non-adherent and is now taking medication properly 4

The diagnosis is straightforward: exogenous subclinical hyperthyroidism due to levothyroxine overtreatment, and unless there's a specific indication for TSH suppression, the levothyroxine dose should be reduced.